Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737139 · ClinicalTrials.gov registry record · NA
Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine
A NA study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT00737139: Clinical Trial NA study, sponsored by Rush University Medical Center.
NCT00737139 is a NA study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00737139, a NA study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study involves research. The purpose of this research is to formally investigate the hemostatic efficacy of epinephrine to minimize blood loss after total joint arthroplasty. It is unclear if using intra-articular injections of epinephrine in total joint replacement is associated with a decrease in post-operative blood loss. The initial hypothesis is: the use of intra-articular injection of epinephrine is associated with decreased post-operative blood loss.
Interventions
- PROCEDURE Peri-articular injection of marcaine/epinephrine
- PROCEDURE Peri-articular injection of marcaine alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-04 |
| Phase | NA |
Why NCT00737139 stopped before completion
NCT00737139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Peri-articular injection of marcaine/epinephrine is the first listed.
NCT00737139 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00737139 about?
NCT00737139 is a clinical study titled "Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine". This study involves research. The purpose of this research is to formally investigate the hemostatic efficacy of epinephrine to minimize blood loss after total joint arthroplasty. It is unclear if using intra-articular injections of epinephrine in total joint replacement is associated with a decreas...
What is the current status of trial NCT00737139?
This trial is currently terminated. It is a NA study. The enrollment target is 33 participants. The study started on 2008-09. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00737139?
The interventions under investigation include: Peri-articular injection of marcaine/epinephrine (PROCEDURE), Peri-articular injection of marcaine alone (PROCEDURE).
Who is sponsoring clinical trial NCT00737139?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00737139's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia